Evolution of Humoral and Cellular Immunity Post-Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab.
Victoria G HallThi H O NguyenLilith F AllenLouise C RowntreeLukasz KedzierskiBrendon Y ChuaChhay LimNatalie R SaundersEmily KlimevskiGayani S TennakoonJohn F SeymourVikas WadhwaNatalie CainKim L VoSuellen NicholsonTheo KarapanagiotidisDeborah A WilliamsonKarin A ThurskyTimothy SpelmanMichelle K YongMonica A SlavinKatherine KedzierskaBenjamin W TehPublished in: Open forum infectious diseases (2023)
Our study provides proof-of-principle for a pre-exposure prophylaxis strategy and highlights the importance of humoral and cellular immunity post-breakthrough COVID-19 in vaccinated patients with HM.